ガニレリクスの世界市場2021-2026:特許、ジェネリック

LP Informationが発行した調査報告書(LPI21JL16590)
◆英語タイトル:Global Ganirelix Market Growth 2021-2026
◆商品コード:LPI21JL16590
◆発行会社(リサーチ会社):LP Information
◆発行日:2021年7月(※2024年版があります。お問い合わせください。)
◆ページ数:134
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後2-3営業日)
◆調査対象地域:グローバル
◆産業分野:医薬品
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,660 ⇒換算¥541,680見積依頼/購入/質問フォーム
Multi User(20名様閲覧用)USD5,490 ⇒換算¥812,520見積依頼/購入/質問フォーム
Corporate User(閲覧人数制限なし)USD7,320 ⇒換算¥1,083,360見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はLP Information社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。LP Information社の概要及び新刊レポートはこちらでご確認いただけます。

LP Information社の「ガニレリクスの世界市場」調査資料は、南北アメリカ、アジア、ヨーロッパ、中東・アフリカ市場を対象にしており、種類別には、特許、ジェネリックなど、用途別には、多嚢胞性卵巣症候群、排卵誘発剤、起立性不耐性、排卵誘発剤、不妊症などにセグメント区分してまとめました。ガニレリクスのグローバル市場規模、主要地域・主要国別、種類別、用途別の市場予測、主要企業の概要・市場シェア・販売量、市場動向などの情報が掲載されています。
・ガニレリクスの世界市場概要(サマリー)
・ガニレリクスの企業別販売量・売上
・ガニレリクスの企業別市場シェア
・ガニレリクスの世界市場規模 2016年-2021年:種類別(特許、ジェネリック)
・ガニレリクスの世界市場規模 2016年-2021年:用途別(多嚢胞性卵巣症候群、排卵誘発剤、起立性不耐性、排卵誘発剤、不妊症)
・ガニレリクスの南北アメリカ市場規模(アメリカ、カナダ、メキシコなど)
・ガニレリクスのアジア市場規模(日本、中国、韓国、インド、東南アジアなど)
・ガニレリクスのヨーロッパ市場規模(ドイツ、フランス、イギリス、イタリア、ロシアなど)
・ガニレリクスの中東・アフリカ市場(エジプト、南アフリカ、トルコ、GCC諸国など)
・ガニレリクス市場の成長要因・課題・動向
・ガニレリクスの世界市場予測 2021年-2026年
・ガニレリクスの南北アメリカ市場予測(アメリカ、カナダ、メキシコなど)
・ガニレリクスのアジア市場予測(日本、中国、韓国、インド、東南アジアなど)
・ガニレリクスのヨーロッパ市場予測(ドイツ、フランス、イギリス、イタリア、ロシアなど)
・ガニレリクスの中東・アフリカ市場予測(エジプト、南アフリカ、トルコ、GCC諸国など)
・ガニレリクスの世界市場予測:種類別(特許、ジェネリック)
・ガニレリクスの世界市場予測:用途別(多嚢胞性卵巣症候群、排卵誘発剤、起立性不耐性、排卵誘発剤、不妊症)
・主要企業分析
【レポートの概要】

According to this latest study, the 2020 growth of Ganirelix will have significant change from previous year. By the most conservative estimates of global Ganirelix market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2020, from US$ xx million in 2019. Over the next five years the Ganirelix market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2025.

This report presents a comprehensive overview, market shares, and growth opportunities of Ganirelix market by product type, application, key manufacturers and key regions and countries.

Segmentation by type: breakdown data from 2016 to 2021, in Section 2.3; and forecast to 2026 in section 11.7.
Patent
Generic

Segmentation by application: breakdown data from 2016 to 2021, in Section 2.4; and forecast to 2026 in section 11.8.
Polycystic Ovaries Syndrome
Ovarian Stimulation
Orthostatic Intolerance
Controlled Ovarian Stimulation
Infertility

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in Chapter 3.
Organon
Sun Pharm
Merck Sharp and Dohme (MSD)
Ferring Pharmaceuticals
Ambinter
BLD Pharm
Chemenu

【レポートの目次】

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered

2 Executive Summary
2.1 World Market Overview
2.1.1 Global Ganirelix Consumption 2016-2026
2.1.2 Ganirelix Consumption CAGR by Region
2.2 Ganirelix Segment by Type
2.2.1 Patent
2.2.2 Generic
2.3 Ganirelix Sales by Type
2.3.1 Global Ganirelix Sales Market Share by Type (2016-2021)
2.3.2 Global Ganirelix Revenue and Market Share by Type (2016-2021)
2.3.3 Global Ganirelix Sale Price by Type (2016-2021)
2.4 Ganirelix Segment by Application
2.4.1 Polycystic Ovaries Syndrome
2.4.2 Ovarian Stimulation
2.4.3 Orthostatic Intolerance
2.4.4 Controlled Ovarian Stimulation
2.4.5 Infertility
2.5 Ganirelix Sales by Application
2.5.1 Global Ganirelix Sale Market Share by Application (2016-2021)
2.5.2 Global Ganirelix Revenue and Market Share by Application (2016-2021)
2.5.3 Global Ganirelix Sale Price by Application (2016-2021)

3 Global Ganirelix by Company
3.1 Global Ganirelix Sales Market Share by Company
3.1.1 Global Ganirelix Sales by Company (2019-2021)
3.1.2 Global Ganirelix Sales Market Share by Company (2019-2021)
3.2 Global Ganirelix Revenue Market Share by Company
3.2.1 Global Ganirelix Revenue by Company (2019-2021)
3.2.2 Global Ganirelix Revenue Market Share by Company (2019-2021)
3.3 Global Ganirelix Sale Price by Company
3.4 Global Manufacturers Ganirelix Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Ganirelix Product Location Distribution
3.4.2 Players Ganirelix Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2021)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion

4 Ganirelix by Region
4.1 Global Ganirelix by Region
4.1.1 Global Ganirelix Sales by Region
4.1.2 Global Ganirelix Revenue by Region
4.2 Americas Ganirelix Sales Growth
4.3 APAC Ganirelix Sales Growth
4.4 Europe Ganirelix Sales Growth
4.5 Middle East & Africa Ganirelix Sales Growth

5 Americas
5.1 Americas Ganirelix Sales by Country
5.1.1 Americas Ganirelix Sales by Country (2016-2021)
5.1.2 Americas Ganirelix Revenue by Country (2016-2021)
5.2 Americas Ganirelix Sales by Type
5.3 Americas Ganirelix Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC
6.1 APAC Ganirelix Sales by Region
6.1.1 APAC Ganirelix Sales by Region (2016-2021)
6.1.2 APAC Ganirelix Revenue by Region (2016-2021)
6.2 APAC Ganirelix Sales by Type
6.3 APAC Ganirelix Sales by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia

7 Europe
7.1 Europe Ganirelix by Country
7.1.1 Europe Ganirelix Sales by Country (2016-2021)
7.1.2 Europe Ganirelix Revenue by Country (2016-2021)
7.2 Europe Ganirelix Sales by Type
7.3 Europe Ganirelix Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 Middle East & Africa
8.1 Middle East & Africa Ganirelix by Country
8.1.1 Middle East & Africa Ganirelix Sales by Country (2016-2021)
8.1.2 Middle East & Africa Ganirelix Revenue by Country (2016-2021)
8.2 Middle East & Africa Ganirelix Sales by Type
8.3 Middle East & Africa Ganirelix Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Country

9 Market Drivers, Challenges and Trends
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends

10 Marketing, Distributors and Customer
10.1 Sales Channel
10.1.1 Direct Channels
10.1.2 Indirect Channels
10.2 Ganirelix Distributors
10.3 Ganirelix Customer

11 Global Ganirelix Market Forecast
11.1 Global Ganirelix Forecast by Region
11.1.1 Global Ganirelix Forecast by Regions (2021-2026)
11.2.2 Global Ganirelix Revenue Forecast by Regions (2021-2026)
11.2 Americas Forecast by Countries
11.3 APAC Forecast by Region
11.4 Europe Forecast by Countries
11.5 Middle East & Africa Forecast by Countries
11.6 Global Ganirelix Forecast by Type
11.7 Global Ganirelix Forecast by Application

12 Key Players Analysis
12.1 Organon
12.1.1 Organon Organon Company Information
12.1.2 Organon Ganirelix Product Offered
12.1.3 Organon Ganirelix Sales, Revenue, Price and Gross Margin (2019-2021)
12.1.4 Organon Main Business Overview
12.1.5 Organon Latest Developments
12.2 Sun Pharm
12.2.1 Sun Pharm Company Information
12.2.2 Sun Pharm Ganirelix Product Offered
12.2.3 Sun Pharm Ganirelix Sales, Revenue, Price and Gross Margin (2019-2021)
12.2.4 Sun Pharm Main Business Overview
12.2.5 Sun Pharm Latest Developments
12.3 Merck Sharp and Dohme (MSD)
12.3.1 Merck Sharp and Dohme (MSD) Company Information
12.3.2 Merck Sharp and Dohme (MSD) Ganirelix Product Offered
12.3.3 Merck Sharp and Dohme (MSD) Ganirelix Sales, Revenue, Price and Gross Margin (2019-2021)
12.3.4 Merck Sharp and Dohme (MSD) Main Business Overview
12.3.5 Merck Sharp and Dohme (MSD) Latest Developments
12.4 Ferring Pharmaceuticals
12.4.1 Ferring Pharmaceuticals Company Information
12.4.2 Ferring Pharmaceuticals Ganirelix Product Offered
12.4.3 Ferring Pharmaceuticals Ganirelix Sales, Revenue, Price and Gross Margin (2019-2021)
12.4.4 Ferring Pharmaceuticals Main Business Overview
12.4.5 Ferring Pharmaceuticals Latest Developments
12.5 Ambinter
12.5.1 Ambinter Company Information
12.5.2 Ambinter Ganirelix Product Offered
12.5.3 Ambinter Ganirelix Sales, Revenue, Price and Gross Margin (2019-2021)
12.5.4 Ambinter Main Business Overview
12.5.5 Ambinter Latest Developments
12.6 BLD Pharm
12.6.1 BLD Pharm Company Information
12.6.2 BLD Pharm Ganirelix Product Offered
12.6.3 BLD Pharm Ganirelix Sales, Revenue, Price and Gross Margin (2019-2021)
12.6.4 BLD Pharm Main Business Overview
12.6.5 BLD Pharm Latest Developments
12.7 Chemenu
12.7.1 Chemenu Company Information
12.7.2 Chemenu Ganirelix Product Offered
12.7.3 Chemenu Ganirelix Sales, Revenue, Price and Gross Margin (2019-2021)
12.7.4 Chemenu Main Business Overview
12.7.5 Chemenu Latest Developments

13 Research Findings and Conclusion

...

【免責事項】
https://www.globalresearch.jp/disclaimer

★リサーチレポート[ ガニレリクスの世界市場2021-2026:特許、ジェネリック(Global Ganirelix Market Growth 2021-2026)]についてメールでお問い合わせはこちらでお願いします。